Civica
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: China’s healthcare reforms, a blessing or a threat?

Michael Custer, analyst at Solidiance in Shanghai, explains that healthcare service providers will come out on top from China’s healthcare reforms.

Until now, China’s healthcare system has served the rapidly developing country well. China impressively succeeded in its efforts to achieve universal healthcare coverage, bringing the insured rate up from 50% in 2005 to 95% by 2011. And, despite achieving universal coverage – a rarity for developing countries – the country has been able to keep costs relatively in check, spending just 5.5% of GDP on healthcare in 2014.

Two trends, however, are threatening the long-term sustainability of China’s system. First, China is experiencing a rapidly aging population. China’s old age dependency ratio, a reliable predictor of healthcare costs, will match that of modern day Japan by 2045.

Second, more of its population is becoming unhealthy. The rates of many chronic diseases as well as cancer are on the rise in China due to pollution, poor diet and unhealthy lifestyle choices. To put this in perspective, the diabetes rate in China is already higher than that of the US.

Without enforcing any reforms to the current system, these trends will lead to enormous strains on the government’s budget. According to Solidiance’s white paper titled “China Healthcare Reforms: Who Will Survive?”, it is projected that 20% of China’s government budget will be allocated to healthcare by 2045. That figure is nearly double what it is today, and behind only New Zealand and the United States.

Under more realistic scenarios, considering China’s growing health problems and an increased share in healthcare funded by the government, the share of state budget allocated towards healthcare will range from 24% to 33% – figures that are by far the largest in the world.

Without change, China’s current healthcare system will become unaffordable. The latest round of reforms, launched towards the end of 2015, are thus aimed at ensuring sustainability by reducing costs so as to create a more efficient healthcare system to its people.

For foreign medical device manufacturers and pharmaceutical companies, the reforms are especially worrisome, as the government is increasing the downward price pressure on both industries. The pharmaceutical industry, which makes up a much larger portion of healthcare spending in China than the device industry, is expected to feel the initial brunt of regulatory pressure.

Despite the reforms adding additional complexity, it is important to remember that China’s healthcare market is large and growing rapidly, with value projected to surpass US$1 trillion by 2020. With a market of that size, there are endless strategies that both foreign pharmaceutical and medical device companies can pursue to ensure a piece of the pie and capitalise on opportunities in China.

A key strategy suggested for multinational companies is to focus on developing and introducing new products. Innovative drugs and medical devices will continue to demand a premium in post-reform China. Additionally, maintaining the edge that foreign multinationals have in r&d and technology is crucial for future success as another emphasis of the reforms is to increase the technical capabilities of domestic healthcare companies, especially in the medical device sector.

Healthcare service providers, on the other hand, will benefit the most out of these reforms. China’s healthcare system is currently highly centralised. Chinese citizens tend to settle for level 3 public hospitals, widely regarded as the country’s best hospitals, to treat everything ranging from the common cold to cancer.  This results in over-utilisation of level 3 hospitals and under-utilisation of clinics, level 1, and level 2 hospitals. This centralisation and lack of efficiency within the public healthcare system is unsustainable and results in poor quality, especially in specialty medicine, and significantly higher costs for the government.

The ultimate goal of enforcing these reforms is to move the Chinese system towards a more decentralised model such as those employed in Europe. To do this, the government is aiming to administer a hierarchal system of healthcare, encourage the development and utilisation of private facilities, and develop a nationwide system of general practitioners. It is this supportive regulatory environment combined with a growing middle class that is beginning to demand better quality healthcare services that will continue to fuel the growth in the private healthcare industry, resulting in increased foreign investment in the healthcare service sector within China.

The Solidance white paper “China Healthcare Reforms: Who Will Survive?” can be downloaded here.

Posted on: 09/03/2017 UTC+08:00


News

Union Medical Healthcare, the largest aesthetic medical service provider in Hong Kong, has said that it intends to change the use of the proceeds of its IPO.
Hong Kong-listed Hua Han Health Industry Holdings says that it is on course for the examination into the negative reports from Emerson Analytics last year to be completed by Grant Thornton by the end of the third quarter.
Hang Seng-listed China Medical & HealthCare Group expects to record a significant decrease in the loss attributable to the shareholders of the company for the year ended 30 June.
Beijing-based Symbow Medical, which develops surgical navigation devices, has raised Rmb120 million (US$17.8 million) Series A funding led by Huayi Capital. National Emerging Industry Guidance Fund, Shandong Buchang Pharmaceuticals, and Sangel Capital all participated.
International Healthway Corporation (IHC), a Singapore-listed integrated healthcare services and facilities provider, has warned that it expects to post a loss for the first and second quarters of the year. “The loss is mainly attributable to operating loss for 1Q2017 and impairment of certain receivables for 2Q2017, respectively,” the company said in a statement.
Medical glove manufacturer Careplus Group plans to raise M$18.9 million (US$4.4 million) via a private placement of shares. The group plans to sell 48.3 million shares at an indicative price of R$0.39 per share. RHB Investment Bank is managing the deal.
Private investment firm TE Asia Healthcare Partners and the Mother Teresa of Calcutta Medical Centre (MTCMC) in Pampanga have agreed to establish a Ps500 million (US$9.9 million) cancer treatment and management centre. The hospital is owned and operated by Silvermed Corporation.
Medical centre operator Primary Health Care has confirmed guidance for the year at the lower end of its guidance with expected net profits of A$92 million (US$73 million). It also flagged up a write down of A$575 million against its medical centres as the division has been underperforming.



Analysis

In what is starting to resemble a comedy of errors, Wenzhou Kangning Hospital, the largest private psychiatric specialty care service provider in China, is having to start work yet again for its A-share offering.
Singapore-based private equity firm Quadria Capital is expanding its holdings in the region with investments into Vietnam and Singapore from its third investment vehicle, Quadria Capital Fund. Financial details were not disclosed for either transaction.
Mental health is a growing issue for expats; workers and their employers, as well as those relocating independently, according to a recent research study by Aetna International. Expatriate mental health: breaking the silence and ending the stigma, calls for businesses and individuals to take more pre-emptive action to combat the problem, to ensure expats have the vital support they need when relocating or working away from their home country.
A new programme, launched by the Chinese Stroke Association (CSA) and the American Stroke Association (ASA) is aiming to improve the treatment for, and prevention of, cardiovascular and stroke events by helping hospitals and providers consistently adhere to the latest scientific treatment guidelines.
Brisbane-based Oventus has had a good week. First and foremost the sleep disorder device manufacturer has just completed the first tranche of capital raising. It has raised A$6.5 million (US$4.9 million) in a placement of shares at A$0.36 per share. A second tranche to raise A$0.5 million will follow subject to shareholder approval. Bell Potter is managing the deal.
A new report from QBE Insurance, Australia's largest global insurer, reveals that 22% of healthcare companies in Hong Kong have suffered from legal and regulatory compliance issues over the past 12 months. The Risks of Regret report looks at both current and future business challenges and opportunities, and how well-prepared companies are to deal with risks.
“The Asia-Pacific region presents lucrative opportunities for multinational pharmaceutical firms that treat diabetes,” says BMI Research in Singapore in a new report on healthcare in Asia. Fuelled by rapid urbanisation, nutrition transition and increasingly sedentary lifestyles, the epidemic has grown in parallel with the worldwide rise in obesity. Asia’s large population and rapid economic development have made it an epicentre of the epidemic, with India and China the key hotspots in the region, it explains.
Susann Roth, senior social development specialist, Asian Development Bank, explains why the ADB is committed to doubling health sector investments by 2020.


AON

HealthInvestor Asia Summit

Podcasts

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices